GeNeuro Announces Approval of all Resolutions Proposed at 2021 Annual General Meeting
Geneva, Switzerland, June 1, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2021. These included among others: https://geneuro.ch/data/news/GeNeuro-AGM-01062021-EN-1-.pdf